Raul Caso
Overview
Explore the profile of Raul Caso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Caso R, Connolly J, Zhou J, Tan K, Choi J, Jones G, et al.
NPJ Precis Oncol
. 2021 Jul;
5(1):70.
PMID: 34290393
While next-generation sequencing (NGS) is used to guide therapy in patients with metastatic lung adenocarcinoma (LUAD), use of NGS to determine pathologic LN metastasis prior to surgery has not been...
12.
Connolly J, Scarpa J, Gupta H, Tan K, Mastrogiacomo B, Dycoco J, et al.
Br J Anaesth
. 2021 Jul;
127(3):e82-e85.
PMID: 34272058
No abstract available.
13.
Connolly J, Tan K, Mastrogiacomo B, Dycoco J, Caso R, Jones G, et al.
Br J Anaesth
. 2021 Jun;
127(1):75-84.
PMID: 34147159
Background: Opioids have been linked to worse oncologic outcomes in surgical patients. Studies in certain cancer types have identified associations between survival and intra-tumoural opioid receptor gene alterations, but no...
14.
Jones G, Lengel H, Hsu M, Tan K, Caso R, Ghanie A, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33920810
Stage IV non-small cell lung cancer (NSCLC) accounts for 35 to 40% of newly diagnosed cases of NSCLC. The oligometastatic state-≤5 extrathoracic metastatic lesions in ≤3 organs-is present in ~25%...
15.
Jones G, Caso R, Tan K, Mastrogiacomo B, Sanchez-Vega F, Liu Y, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2604-2612.
PMID: 33593884
Purpose: is the most common mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging clinical activity of inhibitors in the metastatic setting. We investigated disease-free survival (DFS)...
16.
Zhang C, Yu Z, Li J, Zu P, Yu P, Wang G, et al.
J Thorac Dis
. 2020 Dec;
12(11):6836-6846.
PMID: 33282385
No abstract available.
17.
18.
Caso R, Jones G, Tan K, Bosl G, Funt S, Sheinfeld J, et al.
Ann Thorac Surg
. 2020 Sep;
111(4):1141-1149.
PMID: 32882201
Background: Outcomes after thoracic metastasectomy in patients with testicular germ cell tumors (GCTs) who received first-line chemotherapy alone versus salvage chemotherapy remain unexplored. Methods: We conducted a retrospective review of...
19.
Caso R, Sanchez-Vega F, Tan K, Mastrogiacomo B, Zhou J, Jones G, et al.
J Thorac Oncol
. 2020 Aug;
15(12):1844-1856.
PMID: 32791233
Introduction: The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histologic subtypes in lung adenocarcinoma (LUAD). Methods: We identified 604...
20.
Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment
Jones G, Caso R, Choe G, Tan K, Connolly J, Dycoco J, et al.
Ann Thorac Surg
. 2020 Aug;
111(3):1028-1035.
PMID: 32739257
Background: Outcomes after segmentectomy compare favorably with those after lobectomy in patients with stage I non-small cell lung cancer (NSCLC). Whether long-term outcomes vary by segmentectomy location is unclear. We...